	US 12,214,049 B2
	Anti-angiogenic antibody-drug conjugates
Jinsong Ni, Irvine, CA (US); and Rong Yang, Mission Viejo, CA (US)
Assigned to ADS Therapeutics LLC, Irvine, CA (US)
Filed by ADS Therapeutics LLC, Reno, NV (US)
Filed on Oct. 8, 2020, as Appl. No. 17/065,901.
Application 17/065,901 is a continuation of application No. 16/072,415, granted, now 10,835,617, previously published as PCT/US2017/016107, filed on Feb. 2, 2017.
Claims priority of provisional application 62/291,361, filed on Feb. 4, 2016.
Prior Publication US 2021/0030889 A1, Feb. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/496 (2006.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); C07K 16/00 (2006.01); C07K 16/22 (2006.01); A61K 47/46 (2006.01)

CPC A61K 47/6803 (2017.08) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 31/496 (2013.01); A61K 39/3955 (2013.01); A61K 47/6845 (2017.08); A61K 47/6849 (2017.08); C07K 16/00 (2013.01); C07K 16/22 (2013.01); A61K 47/46 (2013.01); C07K 2317/24 (2013.01)]

15 Claims

1. A method of treating an ocular disease in a subject, comprising:

delivering to the subject a compound comprising:

bevacizumab or ranibizumab;

a small molecule anti-angiogenesis inhibitor; and

a linker that links the small molecule anti-angiogenesis inhibitor to the bevacizumab or ranibizumab, wherein the linker comprises a bond that can be hydrolyzed in vitreous humor, and wherein the linker is hydrolyzed in the subject over time such that both the bevacizumab or ranibizumab and the small molecule exert their functions in the subject.